Montelukast Glenmark Pharmaceuticals Europe (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding and triggering bronchoconstriction, airway inflammation, and mucus production, which helps keep the airways open and reduces allergic inflammation.

The appropriate dose of Montelukast is determined by a qualified prescriber based on the patient’s age, indication and clinical response. Patients should follow the dosing instructions provided on the prescription label.

Safety data for Montelukast in pregnancy are limited, and the drug is not classified in a specific pregnancy category. It should be used only if the potential benefit justifies any possible risk. Information on breastfeeding is also insufficient, so a risk‑benefit assessment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who prefer a tablet form or have exercise‑induced symptoms, though inhaled steroids remain the first‑line option for many severe asthma cases.

Montelukast tablets should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the product in its original blister pack until use and avoid storing in humid environments such as bathrooms.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water; it is not intended for chewing or crushing.

Serious adverse events include severe allergic reactions (e.g., angioedema, anaphylaxis), mood disturbances such as depression or suicidal thoughts, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with a history of severe psychiatric disorders, liver disease, or those taking strong CYP3A4‑inducing medications.